Related Experiment Video
Updated: Jan 31, 2026

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Treatment Duration of Each Anti-COVID-19 Agent Used in a Tertiary Hospital in Japan
Masafumi Seki1, Kazunori Enami2
1Division of Infectious Disease and Infection Control, Saitama Medical University International Medical Center, Hidaka City, JPN.
Abstract:
Four anti-COVID-19 agents, nirmatrelvir/ritonavir (Nir/r), ensitrelvir (ESV), molnupiravir (MPV), and remdesivir (RDV), have been used in Japan for adult patients, and their clinical effectiveness, especially treatment duration and reduction of viral antigen titers, was investigated. A total of 114 adult cases received anti-COVID-19 treatment (33 Nir/r, 27 ESV, 24 MPV, and 30 RDV) in our hospital on admission, and the viral antigen titers were sufficiently decreased in all 114 patients. However, the treatment durations differed significantly: 4.09 days with Nir/r, 4.76 days with ESV, 4.74 days with MPV, and 5.08 days with RDV. These data suggest that the anti-viral activity of each anti-COVID-19 agent may differ in clinical use.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Hospitals-II
Nurses that work in...
Hospitals-I
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Tertiary Healthcare System
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

